



# **FINANCIAL REPORT**

# REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION

YEARS ENDED DECEMBER 31, 2014 AND 2013

## FINANCIAL REPORT YEARS ENDED DECEMBER 31, 2014 AND 2013

## CONTENTS

	<u>Page</u>
INDEPENDENT AUDITORS' REPORT ON THE FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION	1 - 2
FINANCIAL STATEMENTS	
Statements of Financial Position	3
Statements of Activities and Changes in Net Assets	4
Statements of Cash Flows	5
Notes to Financial Statements	6 - 8
SUPPLEMENTARY INFORMATION	



#### INDEPENDENT AUDITORS' REPORT

To the Board of Directors Reagan-Udall Foundation for the Food and Drug Administration Washington, D.C.

#### Report on the Financial Statements

We have audited the accompanying financial statements of Reagan-Udall Foundation for the Food and Drug Administration, which comprise the statements of financial position as of December 31, 2014 and 2013, and the related statements of activities and changes in net assets and cash flows for the years then ended, and the related notes to the financial statements.

#### Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

#### Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Reagan-Udall Foundation for the Food and Drug Administration as of December 31, 2014 and 2013, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### **Report on Supplementary Information**

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The schedules of functional expenses on page 9 are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Jampson Greenspon

Fairfax, Virginia November 16, 2015

# STATEMENTS OF FINANCIAL POSITION DECEMBER 31, 2014 AND 2013

	2014	2013	
ASSETS			
Current Assets			
Cash and cash equivalents	\$ 468,775	\$ 479,527	
Grants receivable, current portion	1,679,448	700,000	
Prepaid expenses	73,611	53,862	
Total Current Assets	2,221,834	1,233,389	
Property and Equipment			
Property and equipment	9,716	7,912	
Website	33,786	33,786	
Accumulated depreciation	(34,731)	(19,417)	
Net Property and Equipment	8,771	22,281	
Other Assets			
Grants receivable, net of current portion	-	207,010	
Security deposits	17,600	15,660	
Total Other Assets	17,600	222,670	
Total Assets	\$ 2,248,205	\$ 1,478,340	
LIABILITIES AND NET ASSETS			
Current Liabilities	0 050 450	• • • • • • • •	
Accounts payable	\$ 656,153	\$ 418,823	
Grant refund payable	255,061	-	
Accrued wages	16,942	12,240	
Total Current Liabilities	928,156	431,063	
Net Assets			
Unrestricted	-	95,327	
Temporarily restricted	1,320,049	951,950	
Total Net Assets	1,320,049	1,047,277	
Total Liabilities and Net Assets	\$ 2,248,205	\$ 1,478,340	

The Notes to Financial Statements are an integral part of these statements.

\_\_\_\_

# STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS YEARS ENDED DECEMBER 31, 2014 AND 2013

		2014		2013				
	Temporarily			Temporarily				
	Unrestricted	Restricted	Total	Unrestricted	Restricted	Total		
Support and Revenue								
Contributions	\$ 21,108	\$ 52,600	\$ 73,708	\$ 395	\$-	\$ 395		
Grants	315,526	3,889,419	4,204,945	150,000	4,016,446	4,166,446		
Net assets released from								
restrictions	3,573,920	(3,573,920)	<b>-</b>	3,885,034	(3,885,034)			
Total Support and Revenue	3,910,554	368,099	4,278,653	4,035,429	131,412	4,166,841		
Expenses								
Programs	3,573,920	-	3,573,920	3,579,276	-	3,579,276		
Development	16,058	-	16,058	8,846	-	8,846		
Management and general	415,903	<u></u>	415,903	477,848		477,848		
Total Expenses	4,005,881		4,005,881	4,065,970		4,065,970		
Change in Net Assets	(95,327)	368,099	272,772	(30,541)	131,412	100,871		
Net Assets, beginning of year	95,327	951,950	1,047,277	125,868	820,538	946,406		
Net Assets, end of year	<u> </u>	\$ 1,320,049	\$ 1,320,049	\$ 95,327	\$ 951,950	\$ 1,047,277		

The Notes to Financial Statements are an integral part of these statements.

# STATEMENTS OF CASH FLOWS YEARS ENDED DECEMBER 31, 2014 AND 2013

	2014		2013	
Cash Flows from Operating Activities	<del></del>		•	
Change in net assets	\$	272,772	\$	100,871
Adjustments to reconcile change in net assets to				·
net cash used by operating activities				
Depreciation and amortization		15,314		12,057
(Increase) Decrease in		·		·
Grants receivable		(772,438)		(907,010)
Prepaid expenses		(19,749)		(43,515)
Increase (Decrease) in		,		· · · /
Accounts payable		237,330		217,546
Grant refund payable		255,061		-
Accrued wages		4,702		8,041
Net Cash Used by Operating Activities		(7,008)		(612,010)
Cash Flows from Investing Activities				
Increase in security deposits		(1,940)		(5,880)
Payments for the purchase of property		(1,804)		(8,027)
· · · · ·	•			
Net Cash Used by Investing Activities		(3,744)		(13,907)
Net Decrease in Cash and Cash Equivalents		(10,752)		(625,917)
Cash and Cash Equivalents, beginning of year		479,527	·	1,105,444
Cash and Cash Equivalents, end of year	\$	468,775	\$	479,527

The Notes to Financial Statements are an integral part of these statements.

## NOTES TO FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2014 AND 2013

#### 1. NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### **Organization and Purpose**

Reagan-Udall Foundation for the Food and Drug Administration, Inc. (the Foundation) is a non-profit organization created by Congress in 2007 and incorporated under the laws of the State of Maryland. The Foundation was in organization until 2009. The Foundation's primary purpose is to advance the mission of the Food and Drug Administration to modernize medical, veterinary, food, food ingredient, and cosmetic product development, accelerate innovation, and enhance product safety pursuant to Section 770 of the Federal Food, Drug, and Cosmetic Act. The Foundation's current projects include the Critical Path to Tuberculosis Drug Regimens Project (CPTR), the Innovation in Medical Evidence Development and Surveillance (IMEDS), the Alzheimer's Association fellowship (AA) and the health outcome of interest in secondary or automated data sources project (HOI). The Foundation is currently located in Washington, D.C.

The activities of the Foundation are financed by grants, contributions, and the Food and Drug Administration (the FDA) funds specifically prescribed under the statute to be appropriated to the FDA and then transferred to the Foundation. The Commissioner of the FDA shall transfer not less than \$500,000 and not more than \$1,250,000 for each fiscal year. Funds received from the FDA are to be utilized for the core operations of the Foundation to include strategic planning.

#### **Basis of Accounting**

The financial statements of the Foundation have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles. Accordingly, revenue is recognized when earned and expenses are recognized when incurred.

#### **Estimates**

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

#### Support and Revenue

The Foundation reports gifts of cash and other assets as restricted support if they are received with donor stipulations that limit the use of the donated assets.

Grants receivable represents amounts which have been promised but not yet received. All grants receivable are expected to be collectable. Various grants received by the Foundation periodically require progress reports on the activities of the Foundation.

#### Cash and Cash Equivalents

For the purposes of the statements of cash flows, cash equivalents include demand deposits and certificates of deposit with original maturities of three months or less.

The Foundation maintains its cash accounts with one financial institution which, at times, may exceed Federally insured limits of \$250,000. The Foundation has not experienced any losses from such accounts.

## NOTES TO FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2014 AND 2013

# 1. NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

#### **Property and Equipment**

The Foundation has a capitalization policy for qualifying assets in excess of \$1,000. Computer equipment and website charges are reported at cost. Assets are depreciated over a three year estimated life using the straight-line method. Depreciation and amortization expense for the years ended December 31, 2014 and 2013 was \$15,314 and \$12,057, respectively.

#### **Net Assets**

Unrestricted net assets are those that are not subject to donor-imposed stipulations. Amounts received that are designated for future periods or restricted by the donor for specific purposes are reported as temporarily restricted or permanently restricted support that increases those net asset classes. When a restriction expires, that is, when a stipulated time or purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statements of activities and changes in net assets as net assets released from restrictions.

#### **Functional Allocation of Expenses**

The costs of providing various programs and other activities have been summarized on a functional basis in the statements of activities and changes in net assets. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

#### Income Tax Status

Under Section 501(c)(3) of the Internal Revenue Code and the applicable income tax regulations of the State of Maryland, the Foundation is exempt from taxes on income related to its exempt purpose.

The Foundation has no uncertain tax positions that qualify for either recognition or disclosure in the financial statements and no interest and penalties have been recorded in the accompanying financial statements related to uncertain tax positions.

The Foundation files Form 990, Return of Organization Exempt from Income Tax, with the Internal Revenue Service. Currently, the 2013, 2012 and 2011 income tax returns are open and subject to examination. The Foundation is not currently under audit by any income tax jurisdiction.

#### **Donated Services**

Donated professional services are recognized at their fair value when the services are rendered. During the years ended December 31, 2014 and 2013 the Foundation received \$52,600 and \$-0-, respectively, in donated services.

#### Subsequent Events

The date to which events occurring after December 31, 2014, the date of the most recent statement of financial position, have been evaluated for possible adjustment to the financial statements or disclosure is November 16, 2015, which is the date on which the financial statements were available to be issued.

## NOTES TO FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2014 AND 2013

#### 2. GRANT REFUND PAYABLE

Subsequent to the date of the statement of financial position, the Foundation returned \$255,061 of unexpensed grant funds to the original donor. The original grant funds were received and recorded as temporarily restricted revenue in 2011, with the grant period ending during 2014. During 2014, the Foundation received additional grant monies from this donor, and the grant refund payable is netted against the amount received for the year ending December 31, 2014.

#### 3. TEMPORARILY RESTRICTED NET ASSETS

Temporarily restricted net assets released from restrictions and the remaining temporarily restricted net assets are as follows at December 31:

	20	14	2013			
	Released	Temporarily	Released	Temporarily		
	from	Restricted	Restricted from			
	Restriction	Net Assets	Restriction	Net Assets		
IMEDS	\$ 3,107,939	\$ 186,939	\$ 3,031,006	\$ 222,439		
AA	33,285	373,665	6,050	406,951		
CPTR	195,622	759,445	194,856	322,560		
FDA	184,474	-	653,122	-		
HOI	52,600		-			
Totals	\$ 3,573,920	\$ 1,320,049	\$ 3,885,034	\$ 951,950		

#### 4. CONCENTRATION OF RISK

At December 31, 2014 and 2013, seven entities accounted for 96 percent of revenue, and one entity accounted for 12 percent of revenue, respectively. At December 31, 2014 and 2013, four and three entities accounted for all of the grants receivable, respectively.

During 2013, approximately \$313,000 of funds was received by the Foundation to continue work on the Observational Medical Outcomes Partnership (OMOP), which had been housed at the Foundation for the National Institute of Health. The funds received and related expenses are included with the Foundation's IMEDS program.

#### 5. LEASE COMMITMENTS

In October 2011, the Foundation entered into a lease for office space in Washington, D.C., which commenced in November 2011. The Foundation entered into leases for additional office space within the same building during 2013. All the leases automatically renew every 6 months if termination notice is not given to the landlord within 60 days of expiration. The leases are currently scheduled to expire on December 15, 2015. These leases include various services such as furniture rental. Future minimum lease payments under these noncancelable operating leases at December 31, 2015 is \$169,300.

Rent expense for the years ended December 31, 2014 and 2013 was \$171,314 and \$157,824, respectively.

## SCHEDULES OF FUNCTIONAL EXPENSES YEARS ENDED DECEMBER 31, 2014 AND 2013

	2014			2013				
	Programs	Development	Management and General	Total	Programs	Development	Management and General	Total
Salaries and fringe benefits	\$ 556,441	\$ 9,344	\$ 149,237	\$ 715,022	\$ 287,083	\$ 5,968	\$ 151,339	\$ 444,390
Travel, meetings, and conferences	101,637	4,236	8,793	114,666	208,204	558	22,005	230,767
Occupancy	144,886	2,433	38,858	186,177	111,095	2,309	58,565	171,969
Office and communication								• -
expenses	646,658	45	31,041	677,744	502,850	11	44,692	547,553
Professional services	2,124,298		187,974	2,312,272	2,470,044	<u> </u>	201,247	2,671,291
Totals	\$ 3,573,920	<u>\$ 16,058</u>	\$ 415,903	\$ 4,005,881	\$ 3,579,276	<u>\$ 8,846</u>	\$ 477,848	\$ 4,065,970